PVLA — Palvella Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $270.11m
- $186.51m
- 39
- 26
- 70
- 42
Annual cashflow statement for Palvella Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37.2 | -45.7 | -33.3 | -24.5 | -17.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.24 | 5.09 | 3.94 | 17 | 6.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -16.4 | 30.5 | -33.4 | -48.1 | -0.193 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45.9 | -7.66 | -59.9 | -53.8 | -10.8 |
| Capital Expenditures | -2.73 | -0.949 | -1.04 | -0.171 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 41.9 | 0 | -20.2 | 12.2 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 39.2 | -0.949 | -21.2 | 12 | — |
| Financing Cash Flow Items | 0.2 | 0.165 | 0.197 | 0.066 | 8.65 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.1 | 59.1 | 7.21 | 19.8 | 87.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.18 | 47.3 | -79.1 | -21.2 | 76.3 |